LISATA THERAPEUTICS, INC. 8-K

What Happened

• Lisata Therapeutics, Inc. announced a binding term sheet dated January 20, 2026 with Kuva Labs Inc. under which Kuva agreed to negotiate a purchase agreement to acquire Lisata. Under the proposed transaction Kuva would launch a tender offer to buy, on a fully-diluted basis, all outstanding Lisata common stock and, if successful, complete a short‑form merger under Section 251(h) of the Delaware General Corporation Law.
• On February 27, 2026 Lisata and Kuva executed an amendment to that term sheet to extend its expiration date to March 7, 2026. The tender offer has not commenced; Kuva intends to file a Schedule TO and Lisata will file a Solicitation/Recommendation Statement on Schedule 14D‑9 when materials are available.

Key Details

• Original term sheet date: January 20, 2026; Term Sheet Amendment executed: February 27, 2026 extending expiration to March 7, 2026.
• Transaction structure: Kuva to commence a tender offer for all Lisata shares (fully diluted basis) followed by a short‑form merger (Delaware Section 251(h)).
• Tender offer materials will be filed on Schedule TO by Kuva; Lisata will file a Schedule 14D‑9 recommending action to stockholders.
• The Term Sheet Amendment is filed as Exhibit 10.1 to the Form 8‑K.

Why It Matters

• The deal, if completed, would result in a change of control for Lisata and could materially affect shareholders (e.g., cash-out or ownership change). Timing and completion are uncertain—closing depends on entering a definitive purchase agreement, tender participation levels, and satisfaction or waiver of closing conditions.
• Investors should watch for the Schedule TO and Lisata’s Schedule 14D‑9 (when filed) for full deal terms and the company’s recommendation. The 8‑K also highlights risks the company identified (possible competing offers, management distraction, litigation risk), so holders should review the formal tender and solicitation materials before deciding.